GT Biopharma GTBP
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
About
GT Biopharma (GTBP) Business Model and Operations Summary
GT Biopharma Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products in the United States. It is engaged in discovering, developing, and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its TriKE (Tri-specific Killer Engager) platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.
Key Insights
GT Biopharma (GTBP) Core Market Data and Business Metrics
Latest Closing Price
$2.71Market Cap
$7.47 MillionTotal Outstanding Shares
2.59 Million SharesTotal Employees
1IPO Date
February 11, 2021SIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
505 Montgomery Street, San Francisco, CA, 94111
Earnings Reports
Expected vs. Actual Quarterly Earnings-Per-Share & Revenue
Short Volume
Daily short volume activity identifies short-term trading pressure and potential price volatility
Revenue Breakdown
Distribution of revenue across unique business segments & geographies
Historical Stock Splits
Execution Date | Split Amount |
---|